ENTPD1 and breast cancer: In the follow-up collection phase, where an alteration in the nucleotide hydrolysis profile or, at the very least, a shift in AMPase activity was expected due to the observed trend of increased CD39 expression in the EVs, our results did not corroborate the earlier reported findings in patients with breast cancer [26].